Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.
Calculus Capital is a pioneer of tax efficient investing, having launched the UK’s first approved EIS Fund in 1999. We offer an opportunity to invest in a portfolio of entrepreneurial UK growth businesses, through our award winning Calculus EIS Funds and Calculus VCT. We invest in the fastest growing sectors of the UK economy – technology, healthcare and creative industries.
Please note, tax treatment depends on the individual circumstances of each investor and may be subject to change in the future.
Looking to invest?
Learn about the tax-efficient investment opportunities offered by our Calculus EIS Fund and Calculus VCT
We would be delighted to learn about your business and discuss whether Calculus could be a suitable investment partner